1. Advice on agalsidase alfa (Replagal®) and agalsidase beta (Fabrazyme®) for the indication ‘Fabry disease’. Diemen: CVZ, 2012. http://www.cvz.nl/binaries/content/documents/cvzinternet/nl/documenten/rubriek+zorgpakket/acp/1209/acp1209-7a-agalsidase.pdf . Accessed 17 Oct 2012.
2. Advice on alglucosidase alfa (Myozyme®) for the indication ‘Pompe disease’. Diemen: CVZ, 2012. http://www.cvz.nl/binaries/content/documents/cvzinternet/nl/documenten/rubriek+zorgpakket/acp/1209/acp1209-08a-alglucosidase.pdf . Accessed 17 Oct 2012.
3. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42.
4. NICE to assess high cost low volume drugs. London: Department of Health, 2012. http://www.dh.gov.uk/health/2012/07/very-high-cost-drugs/ . Accessed 17 Oct 2012.
5. Sheldon T. Dutch doctors call for EU evaluation of cost effectiveness of high cost orphan drugs. BMJ. 2012;345:e5461.